Prostate stem cell
AssigneeProcure Therapeutics Limited
InventorsNorman James Maitland, Anne Collins
Life of this patent
Estimating the term…
Abstract
We describe a method for the isolation of prostate stem cells, typically prostate stem cells which express CD 133 antigen; stem cells and cancer stem cells isolated by the method and their use.
Claims10
A method for the selective enrichment of prostate cancer stem cells which express CD133, CD44, and high levels of α2β1 integrin which comprises the following steps:
- i) providing a cell preparation comprising prostate cancer stem cells derived from prostate tissue;
- ii) providing cell culture conditions which allow the maintenance of said prostate cancer stem cells in culture and the binding of said prostate cancer stem cells to a collagen based matrix;
- iii) selecting said bound cells for expression of CD133 and isolating bound cells that express CD133 antigen, CD44 antigen, and α2β1 integrin.
A cell culture of prostate cancer stem cells wherein said cells express CD133 antigen, CD44 antigen, and α2β1 integrin wherein said prostate cancer stem cells have high in vitro proliferative potential, have higher colony forming efficiency than α2β1 integrinlow CD 133− prostate cells and can form cancerous prostatic-like acini in an immune-compromised non-human animal model.
Dependencies are inferred from the claim text.